[Table/Fig-3]:

Study design, blinding and evaluation period.

Randomized clinical trial	Parallel design	Cross-over Design	Single blind	Double blind	Triple blind	No mention of blinding	Baseline evaluation
Turkoglu O et al., [2]	√	-	-	√	-	-	√
Jhingta P et al., [3]	√	-	-	-	-	√	-
Albert-Kiszely A et al., [7]	√	-	-	√	-	-	√
Arora V et al., [15]	-	√	-	√		-	√
Harini PM et al., [20]	√	-	-	√		-	√
Najafi MH et al., [22]	√	-	-	√		-	√
Mythri H et al., [23]	√	-	√	-	-	-	√
Sharma N et al., [24]	√	-	√	-	-	-	√
Pilloni A et al., [28]	-	√	-	-	-	√	√
Pedrazzi V et al., [29]	√	-	-	-	√	-	√